-+ 0.00%
-+ 0.00%
-+ 0.00%
Allarity Therapeutics Receives U.S. Patent Covering Stenoparib Treatment Regimens Into 2045
Share
Listen to the news

The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity's clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

The patent complements Allarity's previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. Together, these patents enable the Company's strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending